Amgen and UCB Team Up with NASA
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) are collaborating with the National Aeronautics and Space Administration (NASA) Ames Research Center to conduct a preclinical test of a sclerostin antibody in an experiment that will take place aboard space shuttle Atlantis,
London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency
- Details
- Category: GlaxoSmithKline
London 2012 partner GlaxoSmithKline (GSK) signed a long-term agreement with the World Anti-Doping Agency (WADA) that will help the agency create early detection methods for medicines that have performance-enhancing potential in sport.
Novartis receives FDA approval for Arcapta(TM) Neohaler(TM)
- Details
- Category: Novartis
Novartis announced that the US Food and Drug Administration (FDA) has approved once-daily Arcapta(TM) Neohaler(TM) (indacaterol inhalation powder) 75 mcg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema[1].
Pfizer and ChemRar to Explore Innovative Medical Research and Development Partnership in Russia
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and the Russian pharmaceutical investment and R&D group ChemRar High Tech Center (ChemRar) have signed a Memorandum of Understanding (MoU) to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries.
Bayer advances research in the area of pulmonary hypertension
- Details
- Category: Bayer
Bayer HealthCare is working with the Ludwig Boltzmann Institute (LBI) for Lung Vascular Research in the research area of lung vascular diseases - especially pulmonary hypertension.
AstraZeneca and PTC Therapeutics announce strategic oncology drug discovery collaboration
- Details
- Category: AstraZeneca
AstraZeneca and PTC Therapeutics, Inc. (PTC) have entered into an exclusive research collaboration and license agreement for the application of PTC's proprietary GEMS™ technology (Gene Expression Modulation by Small-molecules) for the discovery and development of potential new therapies for cancer and other diseases for which there is a great unmet medical need.
Pfizer Files with the FDA for Review of Axitinib for Patients with Advanced Renal Cell Carcinoma
- Details
- Category: Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Pfizer's filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC).
More Pharma News ...
- Bristol-Myers Squibb to Expand Access to Reyataz® in sub-Saharan Africa and India
- Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control
- Bristol-Myers Squibb Foundation Awards $1.5 Million in Grants
- Merck: Regulatory Update on Cladribine Tablets
- Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
- Boehringer Ingelheim and Ashoka announce a global partnership for "Making More Health"
- Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases